Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial

NCT07722754 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms Malignant
Neoplasm, Metastatic

Interventions

DRUG: Cetuximab
DRUG: Irinotecan
DRUG: Bevacizumab
DRUG: Sintilimab

Sponsor

Guangdong Provincial People's Hospital